Skip to main content
Der Schmerz
Erschienen in: Der Schmerz 1/2016

01.02.2016 | Schwerpunkt

Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews

verfasst von: Dr. S. Tafelski, W. Häuser, M. Schäfer

Erschienen in: Der Schmerz | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

There is growing public and legislative body support for the medical use of cannabis products, for example, for chemotherapy-induced nausea and vomiting (CINV), in Germany.

Methods

A comprehensive literature search until November 2015 was conducted in MEDLINE, DARE and Cochrane libraries for systematic reviews of randomized controlled trials (RCTs) comparing herbal or pharmaceutical cannabinoids (CB) versus placebo or conventional antiemetics for CINV. Outcomes were reduction of CINV for efficacy, drop-out rates due to adverse events for tolerability, and serious adverse events for safety. The methodology quality of the systematic reviews was evaluated by the tool assessment of multiple systematic reviews (AMSTAR).

Results

Six systematic reviews of RCTs included the pharmaceutical CBs dronabinol, levonantradol, and nabilone or whole plant extract (e.g., nabiximol) compared with placebo or conventional antiemetics. There was moderate quality evidence on the efficacy of CBs compared to placebo and conventional antiemetics for CINV. There was moderate quality evidence that pharmaceutical CBs were less tolerated and less safe than placebo and conventional antiemetics in CINV. One RCT examining whole plant extract was included into the systematic reviews. No RCT was found comparing CBs with neurokinine−1 receptor antagonists.

Conclusions

With safe and effective antiemetics available, CBs cannot be recommended as first- or second-line therapy for CINV. Some guidelines recommend pharmaceutical CBs as third-line treatment in the management of breakthrough nausea and vomiting. Due to the lack of RCT data and safety concerns, herbal cannabis cannot be recommended for CINV.
Literatur
1.
Zurück zum Zitat Ablin JN, Buskila D (2010) Emerging therapies for fibromyalgia: an update. Expert Opin Emerg Drugs 15:521–533 CrossRefPubMed Ablin JN, Buskila D (2010) Emerging therapies for fibromyalgia: an update. Expert Opin Emerg Drugs 15:521–533 CrossRefPubMed
2.
Zurück zum Zitat Aromataris E (2014) Joanna Briggs Institute Reviewers’ Manual: 2014 edition/Supplement. In:Joanna Briggs Institute Aromataris E (2014) Joanna Briggs Institute Reviewers’ Manual: 2014 edition/Supplement. In:Joanna Briggs Institute
3.
Zurück zum Zitat Basch E, Hesketh PJ, Kris MG et al (2011) Antiemetics: American society of clinical oncology clinical practice guideline update. J Oncol Pract 7:395–398 PubMedCentralCrossRefPubMed Basch E, Hesketh PJ, Kris MG et al (2011) Antiemetics: American society of clinical oncology clinical practice guideline update. J Oncol Pract 7:395–398 PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Craver C, Gayle J, Balu S et al (2011) Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 14:87–98 CrossRefPubMed Craver C, Gayle J, Balu S et al (2011) Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 14:87–98 CrossRefPubMed
5.
Zurück zum Zitat Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17:85–95 CrossRefPubMed Davis MP (2008) Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs 17:85–95 CrossRefPubMed
6.
Zurück zum Zitat Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066 CrossRefPubMed Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066 CrossRefPubMed
7.
Zurück zum Zitat Hesketh PJ (2004) Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Williston Park). 18:9–14 PubMed Hesketh PJ (2004) Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Williston Park). 18:9–14 PubMed
8.
Zurück zum Zitat Higgins J, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration. Wiley-Blackwell, Hoboken Higgins J, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration. Wiley-Blackwell, Hoboken
9.
Zurück zum Zitat Hill KP (2015) Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313:2474–2483 CrossRefPubMed Hill KP (2015) Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 313:2474–2483 CrossRefPubMed
10.
Zurück zum Zitat Hoch E, Bonnetn U, Thomasius R et al (2015) Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int 112:271–278 PubMedCentralPubMed Hoch E, Bonnetn U, Thomasius R et al (2015) Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int 112:271–278 PubMedCentralPubMed
11.
Zurück zum Zitat Hocking CM, Kichenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 22:1143–1151 CrossRefPubMed Hocking CM, Kichenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 22:1143–1151 CrossRefPubMed
12.
Zurück zum Zitat Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784 CrossRefPubMed Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784 CrossRefPubMed
13.
Zurück zum Zitat Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090 CrossRefPubMed Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090 CrossRefPubMed
14.
Zurück zum Zitat Keeley PW (2009) Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clin Evid 2009 Keeley PW (2009) Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clin Evid 2009
15.
Zurück zum Zitat Kreienberg R, Albert US, Follmann M et al (2013) Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: short version – AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL – Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd 73:556–583 PubMedCentralCrossRefPubMed Kreienberg R, Albert US, Follmann M et al (2013) Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: short version – AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL – Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd 73:556–583 PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Liu J, Tan L, Zhang H et al (2015) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care (Engl) 24:436–443 CrossRef Liu J, Tan L, Zhang H et al (2015) QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist. Eur J Cancer Care (Engl) 24:436–443 CrossRef
17.
Zurück zum Zitat Machado Rocha FC, Stefano SC, De Cassia Haiek R et al (2008) Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 17:431–443 CrossRef Machado Rocha FC, Stefano SC, De Cassia Haiek R et al (2008) Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 17:431–443 CrossRef
18.
Zurück zum Zitat Palli SR, Grabner M, Quimbo RA et al (2015) The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag Res 7:175–188 PubMedCentralPubMed Palli SR, Grabner M, Quimbo RA et al (2015) The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag Res 7:175–188 PubMedCentralPubMed
19.
Zurück zum Zitat Phillips RS, Gopaul S, Gibson F et al. (2010) Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev (9):CD007786 Phillips RS, Gopaul S, Gibson F et al. (2010) Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev (9):CD007786
20.
Zurück zum Zitat Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–243 CrossRefPubMed Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–243 CrossRefPubMed
21.
Zurück zum Zitat Santana TA, Trufelli DC, Matos LL et al (2015) Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer 23:213–222 CrossRefPubMed Santana TA, Trufelli DC, Matos LL et al (2015) Meta-analysis of adjunctive non-NK1 receptor antagonist medications for the control of acute and delayed chemotherapy-induced nausea and vomiting. Support Care Cancer 23:213–222 CrossRefPubMed
22.
Zurück zum Zitat Seo HJ, Kim KU (2012) Quality assessment of systematic reviews or meta-analyses of nursing interventions conducted by Korean reviewers. BMC Med Res Methodol 12:129 PubMedCentralCrossRefPubMed Seo HJ, Kim KU (2012) Quality assessment of systematic reviews or meta-analyses of nursing interventions conducted by Korean reviewers. BMC Med Res Methodol 12:129 PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Shea BJ, Hamel C, Wells GA et al (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62:1013–1020 CrossRefPubMed Shea BJ, Hamel C, Wells GA et al (2009) AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 62:1013–1020 CrossRefPubMed
24.
Zurück zum Zitat Smith LA, Azariah F, Lavender VT et al. (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 11:CD009464 PubMed Smith LA, Azariah F, Lavender VT et al. (2015) Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 11:CD009464 PubMed
25.
Zurück zum Zitat Todaro B (2012) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 10:487–492 PubMed Todaro B (2012) Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 10:487–492 PubMed
26.
Zurück zum Zitat Tramer MR, Carroll D, Campbell FA et al (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:16–21 PubMedCentralCrossRefPubMed Tramer MR, Carroll D, Campbell FA et al (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323:16–21 PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Van Den Elsen GA, Ahmed AI, Lammers M et al (2014) Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev 14:56–64 CrossRefPubMed Van Den Elsen GA, Ahmed AI, Lammers M et al (2014) Efficacy and safety of medical cannabinoids in older subjects: a systematic review. Ageing Res Rev 14:56–64 CrossRefPubMed
28.
Zurück zum Zitat Van Sickle MD, Duncan M, Kingsley PJ et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332 CrossRefPubMed Van Sickle MD, Duncan M, Kingsley PJ et al (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310:329–332 CrossRefPubMed
29.
Zurück zum Zitat Wang XF, Feng Y, Chen Y et al (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Scientific reports 4:4813 PubMed Wang XF, Feng Y, Chen Y et al (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Scientific reports 4:4813 PubMed
30.
Zurück zum Zitat Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313:2456–2473 CrossRefPubMed Whiting PF, Wolff RF, Deshpande S et al (2015) Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313:2456–2473 CrossRefPubMed
Metadaten
Titel
Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting—a systematic review of systematic reviews
verfasst von
Dr. S. Tafelski
W. Häuser
M. Schäfer
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Der Schmerz / Ausgabe 1/2016
Print ISSN: 0932-433X
Elektronische ISSN: 1432-2129
DOI
https://doi.org/10.1007/s00482-015-0092-3

Weitere Artikel der Ausgabe 1/2016

Der Schmerz 1/2016 Zur Ausgabe

Update AINS

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.